116 related articles for article (PubMed ID: 37926648)
61. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
[No Abstract] [Full Text] [Related]
62. Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Jomrich G; Kollmann D; Ramazanova D; Ristl R; Grose RP; Ilhan-Mutlu A; Preusser M; Fassnacht C; Tsai YC; Guenova E; Schoppmann SF
Eur J Surg Oncol; 2022 Feb; 48(2):383-390. PubMed ID: 34404561
[TBL] [Abstract][Full Text] [Related]
63. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
[TBL] [Abstract][Full Text] [Related]
64. Feasibility of intravoxel incoherent motion diffusion-weighted imaging in distinguishing adenocarcinoma originated from uterine corpus or cervix.
Zhang Q; Ouyang H; Ye F; Song Y; Xie L; Zhao X; Yu X
Abdom Radiol (NY); 2021 Feb; 46(2):732-744. PubMed ID: 32671441
[TBL] [Abstract][Full Text] [Related]
65. Correlation of CT parameters and PD-L1 expression status in gastric cancer.
Xu M; Ren T; Deng J; Yang J; Lu T; Xi H; Yuan L; Zhang W; Zhou J
Abdom Radiol (NY); 2024 Apr; 49(4):1320-1329. PubMed ID: 38436699
[TBL] [Abstract][Full Text] [Related]
66. The co-expression of CBX8 and PD-L1 and prognostic value in cervical cancer.
Zhou H; Li A; Li C; Wu M; Jin D; Shui M
Medicine (Baltimore); 2021 Aug; 100(34):e27056. PubMed ID: 34449496
[TBL] [Abstract][Full Text] [Related]
67. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
68. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
69. Nocardia Rubra Cell Wall Skeleton Up-Regulates T Cell Subsets and Inhibits PD-1/PD-L1 Pathway to Promote Local Immune Status of Patients With High-Risk Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia.
Chen W; Zhang Y; Zhao C; Shao S; Zhang Y; Li X; Bai X; Guo Q; Liu Q; Tang J; Zhang L
Front Immunol; 2020; 11():612547. PubMed ID: 33552075
[TBL] [Abstract][Full Text] [Related]
70. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
71. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway.
Wang S; Li J; Xie J; Liu F; Duan Y; Wu Y; Huang S; He X; Wang Z; Wu X
Oncogene; 2018 Jul; 37(30):4164-4180. PubMed ID: 29706653
[TBL] [Abstract][Full Text] [Related]
72. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
73. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
74. B-Value Optimization in the Estimation of Intravoxel Incoherent Motion Parameters in Patients with Cervical Cancer.
Perucho JAU; Chang HCC; Vardhanabhuti V; Wang M; Becker AS; Wurnig MC; Lee EYP
Korean J Radiol; 2020 Feb; 21(2):218-227. PubMed ID: 31997597
[TBL] [Abstract][Full Text] [Related]
75. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
76. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
77. Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.
Gao S; Du S; Lu Z; Xin J; Gao S; Sun H
Eur Radiol; 2020 Feb; 30(2):1191-1201. PubMed ID: 31493211
[TBL] [Abstract][Full Text] [Related]
78. Assessment of Cervical Cancer with a Parameter-Free Intravoxel Incoherent Motion Imaging Algorithm.
Becker AS; Perucho JA; Wurnig MC; Boss A; Ghafoor S; Khong PL; Lee EYP
Korean J Radiol; 2017; 18(3):510-518. PubMed ID: 28458603
[TBL] [Abstract][Full Text] [Related]
79. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
80. IVIM-DWI and MRI-based radiomics in cervical cancer: Prediction of concurrent chemoradiotherapy sensitivity in combination with clinical prognostic factors.
Zhang Y; Zhang K; Jia H; Xia B; Zang C; Liu Y; Qian L; Dong J
Magn Reson Imaging; 2022 Sep; 91():37-44. PubMed ID: 35568271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
